Florbetapir: all 37 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and TauNot yet recruitingNCT06600880Phase 1
• B-amyloid as a Marker for GBM BioimagingNot yet recruitingNCT05820191Phase 2
• Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired SubjectsCompletedNCT04474405Early Phase 1Results posted
• The Role of F-18 Florbetapir in the Early Detection of Cardiac AmyloidosisTerminatedNCT03040427Phase 4Results posted
• Florbetapir Calibration to the Centiloid ScaleCompletedNCT02120664Phase 1Results posted
• The Feasibility of Florbetapir Quantitation in EuropeCompletedNCT02107599Phase 4Results posted
• Evaluation of Reader Training ProcessesCompletedNCT02051790Phase 4Results posted
• The Feasibility of Florbetapir QuantitationCompletedNCT01946243Phase 4Results posted
• Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.CompletedNCT01890343Phase 2Results posted
• Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS PatientsCompletedNCT01767493Phase 4Results posted
• Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive DeclineCompletedNCT01703702Phase 4Results posted
• A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT01662882Phase 2/3Results posted
• A Study of Florbetapir (18F) in Japanese Healthy VolunteersCompletedNCT01660815Phase 1Results posted
• Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)CompletedNCT01565382Phase 3Results posted
• Evaluation of Physician Training Methods to Read Florbetapir-PET ScansCompletedNCT01565369Not applicableResults posted
• Evaluation of PET Scan Timing Relative to AV-45 Injection TimeCompletedNCT01565356Not applicableResults posted
• A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy VolunteersCompletedNCT01565343Phase 1Results posted
• A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy VolunteersCompletedNCT01565330Phase 1Results posted
• A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly VolunteersCompletedNCT01565291Early Phase 1Results posted
• A Study of 18F-AV-45 in Healthy VolunteersCompletedNCT01564706Phase 1Results posted
• Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET ScansCompletedNCT01550549Not applicableResults posted
• Clinical Evaluation of Florbetapir F 18 (18F-AV-45)CompletedNCT01518374Phase 2Results posted
• Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07CompletedNCT01447719Phase 3Results posted
• Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive DeclineCompletedNCT01400425Phase 3Results posted
• Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsCompletedNCT00857532Phase 2Results posted
• Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)CompletedNCT00857506Phase 2Results posted
• Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the BrainCompletedNCT00857415Phase 3Results posted
• Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal IndividualsCompletedNCT00855868Phase 2Results posted
• A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT00702143Phase 2Results posted
• Plasma P-tau2017 and Quantitative Amyloid PET ImagingCompletedNCT05164536Phase 1
• Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET ExaminationStatus unknownNCT04305210Phase 2
• Phase 1 Test-retest Evaluation of [18F]MNI-958 PETCompletedNCT03545789Phase 1
• Cerebral Amyloid Imaging Using Florbetapir (AV-45)CompletedNCT02813434Phase 3
• Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese PhysiciansWithdrawnNCT02029547Not applicable
• Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)CompletedNCT01962753Not applicable
• Effects of Brain Beta-Amyloid on Postoperative CognitionActive, not recruitingNCT01606488Phase 4
• A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)CompletedNCT01503944Phase 1/2

← Florbetapir overview